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Introduction
Tumor necrosis factor (TNF) is a potent proinflammatory
mediator. Experimental and clinical evidence indicates that
TNF is present in high concentrations in the synovial tissue
and fluid of patients with rheumatoid arthritis (RA); it has
been shown to have a major role in the pathogenesis of
rheumatic diseases and other immunologically mediated dis-
orders [1–4]. TNF regulates the cytokine network, induces
cellular recruitment to sites of inflammation, stimulates the
synthesis and release of synovial tissue matrix metallopro-
teinases such as collagenase, downregulates proteoglycan
synthesis in chondrocytes, inhibits osteoblastic collagen pro-
duction, and upregulates osteoclastic activity [5,6].
Two proof-of-concept trials of anti-TNF agents, by Elliott
and colleagues, were conducted with infliximab (Remi-
cade®; Centocor, Inc., Malvern, PA, USA), a monoclonal
anti-TNF antibody, in the early 1990s [7,8]. The first report
describing the administration of anti-TNF antibodies for
the management of human autoimmune disease came
from an open-label infliximab (then designated cA2)
phase I/II trial in 20 patients with active RA [7]. Patients
received either two infusions of infliximab 10mg/kg at
study entry and at week 2, or four infusions of infliximab
5mg/kg at study entry and at days 4, 8, and 12, for a total
dose of 20mg/kg in each group [7]. Clinical and labora-
tory assessments were performed at weeks 1, 2, 3, 4, 6,
and 8, and the best overall responses were observed at
week 6 [7]. At week 6 there were significant clinical
improvements in the Ritchie Articular Index (from a median
of 28 at baseline to a median of 6, P<0.001), in swollen
joint count (from 18 to 5, P<0.001), in the duration of
morning stiffness (from 180 to 5 minutes, P<0.001 by
Mann–Whitney test, adjusted), and in pain scores (from
7.1 to 1.9 units, P<0.001, adjusted) [7]. Results at
week 6 for the laboratory parameters showed significant
decreases in the levels of serum C-reactive protein (from
39.5 to 8mg/l, P<0.001) and also in those of serum
amyloid A and interleukin-6 [7].
The earlier trial was followed by a multi-centre randomized
trial that compared infliximab (given as a single infusion at
low dose [1mg/kg] or high dose [10mg/kg]) with placebo
in 73 patients with active RA [8]. The primary end point
was the achievement at week 4 of a Paulus 20%
response, the components of which include clinical
(tender/swollen joint scores, duration of morning stiff-
ness), observational (patient and physician assessments
of disease severity), and laboratory (erythrocyte sedimen-
tation rate) variables [8]. On the basis of an intent-to-treat
analysis, a greater number of patients reached the primary
end point with infliximab (11 of 25 in the low-dose group,
P=0.0083; 19 of 24 in the high-dose group, P<0.0001)
than with placebo (2 of 24) [8].
Shortly thereafter another anti-TNF agent, the soluble
protein etanercept (Enbrel®; Immunex Corp, Seattle, WA,
USA), was developed and introduced for use in patients
with RA in 1998. Infliximab with concomitant methotrexate
was licensed in 1999, and these two agents became the
first biologic response modifiers approved by the Food
and Drug Administration (FDA) for the management of RA
[9–11]. Since this symposium, the FDA has approved
adalimumab (Humira™; Abbott Laboratories, Abbott Park,
IL, USA) for the treatment of patients with RA [12]. In
2000 a consensus panel of rheumatology experts empha-
sized that a hierarchy of disease-modifying antirheumatic
drugs (DMARDs)/biologics exists and that biologics might
be appropriate to use at any time during therapy depend-
ing upon disease and response; further, anti-TNF agents
should not be used solely for advanced disease [13].
Unlike the conventional DMARDs, the TNF biologic
response modifiers are genetically engineered (that is,
developed by means of recombinant technology) and
specifically target TNF; they therefore have an adverse
event profile that in some respects is different from that
seen with the DMARDs (for example, those related to
hepatic, pulmonary, hematologic, and gastrointestinal
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systems) [9,14,15]. Data from randomized clinical trials
have not demonstrated an increased frequency of serious
adverse events with the use of anti-TNF agents, although
concerns about their short-term and long-term safety have
been raised in postmarketing surveillance [16]. In spite of
this, the anti-TNF agents have become widely used and
have changed the practice of RA therapy. Infliximab and
etanercept had been administered to more than 271,000
patients as of February 2002 (data on file; Centocor, Inc.)
and to 121,000 patients by September 2001 (data on file;
Immunex Corp). The administration of TNF antagonists
has resulted in an inhibition of structural damage, rapid
and substantial improvement in signs and symptoms, and
improvement in physical function and quality of life for
patients with RA.
The three anti-TNF agents have distinctly different pharma-
cokinetic and pharmacodynamic properties, including dif-
ferences in chemical structure, receptor binding
characteristics, serum half-lives, and routes of parenteral
administration [17]. Although there have been no direct
comparisons of these agents, sufficient clinical data have
accumulated for investigators and clinicians to gauge the
efficacy and safety of all three TNF antagonists and to
assess the dosing methods and schedules.
On 27 October 2002, a panel of experts in rheumatology
assembled in New Orleans, Louisiana, to debate these
issues and place the new anti-TNF agents in perspective.
The symposium was conducted in two segments. The first
part dealt with the efficacy, safety, and route of administra-
tion of the three anti-TNF agents for the management of
RA, and the second consisted of discussions pertaining to
spondyloarthropathies (namely ankylosing spondylitis,
psoriatic arthritis) for the then-available anti-TNF agents,
infliximab and etanercept. This supplement represents the
sum of the experts’ efforts.
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